galinarum AIB-39 or with the susceptible control Enterococcusfaecalis ATCC 29212. Further testing of two type B strains (E.faecalis V583 and V583-2) showed that certain other amino acids (i.e., D-methionine, D-serine, n-alanine, and D-phenylalanine) had effects similar to that of glycine. Results of sodium dodecyl sulfatepolyacrylamide gel electrophoresis with membrane preparations from these strains revealed the production of vancomycin-inducible proteins of sizes comparable to those described for other enterococcal isolates that exhibit acquired vancomycin resistance. Even in the presence of 0.2 M glycine, the inducible proteins were produced. These results indicate that certain amino acids specifically interfere with the mechanism(s) of acquired vancomycin resistance in enterococci and that the nature of interference probably involves inhibition or circumvention of the inducible proteins' fimctions.
As stated by Reynolds, "The structure of glycopeptides, as well as their unique site and mechanism of action, is likely to ensure that any resistance mechanisms acquired by a gram-positive bacterium will be unusual" (18) . Several recent reports (14, 19, 22, 25) are evidence that some such resistance mechanisms have been acquired by enterococci, and there is every indication that the incidence of this resistance will become more widespread (5, 8, 13) . While investigating the plasmid content of Enterococcus faecalis V583, a strain previously described as the first reported vancomycin-resistant E. faecalis strain isolated in the United States (19) , we noted the inability of V583 to grow in usually subinhibitory concentrations of vancomycin when glycine was present in the growth medium. This finding prompted us to investigate whether this effect was specific for vancomycin-resistant enterococci and to determine whether other amino acids could produce similar effects. The results of these studies are the subject of this report. Additionally, how these findings pertain to current hypotheses concerning glycopeptide resistance mechanisms in enterococci is discussed.
Species identification of all strains was based on the conventional scheme reported by Facklam and Collins (7) . E. faecalis ATCC 29212 was the vancomycin-susceptible control, and Enterococcus gallinarum AIB-39, provided by the Antimicrobics Investigation Branch, Centers for Disease Control, Atlanta, Ga. (20) , represented the enterococcal species known to exhibit intrinsic, noninducible, low-level vancomycin resistance (26) . The previously described Enterococcus faecium 228 (11) mycin resistance (i.e., transferable vancomycin and teicoplanin resistance) and is known to hybridize with a vanA probe developed by Dutka-Malen et al. (6, 23) . E. faecalis KS-2 is a vancomycin-resistant transconjugant obtained by filter mating E. faecium 228 and E. faecalis JH2-2 (12) . E. faecium UCVR-1 is a recent blood culture isolate from the University of Chicago Clinical Microbiology Laboratories. E. faecalis V583 has been described previously (19) , and E. faecalis V583-2 is a high-level, vancomycinresistant derivative of V583 obtained by serial passage on media containing increasing concentrations of vancomycin.
E. faecium UCVR-1, E. faecalis V583, and E. faecalis V583-2 each exhibit type B vancomycin resistance (i.e., teicoplanin susceptibility and nontransferable vancomycin resistance).
Broth macrodilution was performed in 1-ml volumes of unsupplemented brain heart infusion broth (BHIB) (Difco Laboratories, Detroit, Mich.) or broth supplemented with 0.2 M amino acid (Sigma Biochemical Co., St. Louis, Mo.) according to the recommended testing procedures (15) . The chosen concentration of amino acid approximated that being used for the plasmid preparation procedure when the "glycine effect" was first noted. Testing was performed in triplicate for each drug-amino acid-organism combination studied. In every instance, all three MICs were within 1 twofold dilution, and in most cases they were the same. When all three MICs were not identical, the value obtained twice was used.
In the presence of glycine, the decrease in vancomycin MICs for the five most resistant enterococci ranged from 8-to 128-fold after 24 h of incubation ( (Fig. 1) . Notably, both strains still produced the 41-kDa protein when grown in the concentration of glycine that substantially lowers vancomycin MICs. Although not shown in Fig. 1 , the amount of protein produced by both strains increased with the concentration of vancomycin used for induction, and more protein was produced by E. faecalis V583-2 than by the parent strain, E. faecalis V583, which exhibits a lower level of resistance (Table 1 ). An inducible protein of comparable size also was noted with E. faecium 228 and E. faecium UCVR-1 but not with either E. faecalis ATCC 29212 or E. gallinarum AIB-39 (data not shown).
Because vancomycin inhibits cell growth primarily by interfering with transglycosylation (18) and glycine and certain other D-amino acids interfere with transpeptidation (10, 16, 21, 24) , the "amino acid effect" could be due to a synergy between vancomycin and various D-analogs that is unrelated to the underlying vancomycin resistance mechanism. However, results of this study indicate that the effect is due to the specific interference of acquired vancomycinresistant mechanisms. The amino acid effect was observed for each vancomycin-resistant E. faecalis and E. faecium strain, but it was not observed with the susceptible control E. faecalis ATCC 29212 or with E. gallinarum AIB-39, an enterococcal species known to intrinsically exhibit low-level vancomycin resistance (26) . That is, the effect was specific VOL. 36, 1992 ANTIMICROB. AGENTS CHEMOTHER.
for those strains that demonstrated production of a unique membrane protein in response to the presence of vancomycin. A nonspecific synergistic effect would have been observed with all strains, regardless of their levels of resistance.
Two generalizations concerning the nature of specific interference by amino acids with vancomycin resistance can be made. First, the extent of the amino acid effect varies among resistant strains. This may be due to distinct differences between the types of resistance mechanisms, that is, between type A (6) and type B (2) resistance, due to differences between expression of resistance in E. faecalis and that in E. faecium, or it may be a combination of these factors. The eightfold decrease in vancomycin MICs for E. faecium 228, a strain known to hybridize with vanA (23) , was the same as the decrease seen with E. faecalis KS-2, a transconjugant of E. faecium 228. These findings indicate that the extent of interference with resistance is dictated more by the type of resistance than by the species in which resistance is expressed. On the other hand, both E. faecium UCVR-1 and E. faecalis V583 phenotypically exhibit type B resistance, but the extent of the glycine effect on vancomycin MICs for V583 was notably greater than that for E.
faecium UCVR-1 (Table 1) . A definitive explanation for these species-to-species variations will require further studies involving a greater variety of resistant isolates. Secondly, glycine does not inhibit production of the inducible 41-kDa protein, which is comparable to, if not the same as, the inducible proteins described by others as the primary mediators of vancomycin resistance in E. faecalis and E. faecium (1, 2, 6, 11) . Because the protein continues to be produced, amino acid interference probably involves inhibition or circumvention of the protein's function.
Because our results indicate that the amino acid effect is specific for the underlying vancomycin resistance mechanisms, some discussion of these findings in the context of current hypotheses concerning vancomycin resistance is warranted. Reports by Bugg et al. (3, 4) have shown that in a type A strain, resistance is mediated by the interactions of a modified D-alanine:D-alanine ligase (Van A) and a D-specific a-keto acid dehydrogenase (Van H) that results in the synthesis of an altered D-alanyl-X dipeptide (3) or depsipeptide (4) . When these products are incorporated into the terminus of the pentapeptide, they are not bound by vancomycin. Regarding the amino acid effect reported in our study, when certain amino acids are present in excess, they could compete with product X and be incorporated into the dipeptide. Dipeptides containing these amino acids are known to incorporate into the pentapeptide and bind vancomycin (17, 21, 24) . Such termini then may bind vancomycin more effectively than termini containing product X, resulting in a decrease in the level of vancomycin resistance. Another possibility is that an excess of certain amino acids causes a shutdown of the modified ligase-dehydrogenase system and allows normal ligase to synthesize conventional peptidoglycan termini that are susceptible to vancomycin action. Our finding that D-alanine, the normal component of the pentapeptide terminus, decreased the level of vancomycin resistance seems most consistent with this latter possibility.
In addition to the ligase-dehydrogenase system reported by Bugg et al. (3, 4) , Al-Obeid et al. (1) and Gutmann et al. (9) suggest that vancomycin resistance is also partially mediated by D,D-carboxypeptidase activity. This enzyme is thought to decrease the number of D-alanyl-D-alanine termini essential for vancomycin binding by cleaving the terminal D-alanine from the UDP-MurNac-pentapeptide unit or by hydrolyzing the D-alanyl-D-alanine dipeptide before adding it to the UDP-MurNac-tripeptide. Relevant to our findings, the amino acids that decreased vancomycin MICs are known to act as D-alanine analog and to substitute for D-alanine in the pentapeptide terminus (21, 24) . While such modified termini can still bind vancomycin (17), they may not bind the DD-carboxypeptidase thought to mediate resistance and thus preserve some level of vancomycin susceptibility. What is not consistent with this possible mechanism of interference with vancomycin resistance is that vancomycin MICs decreased in the presence of D-alanine and, to a lesser extent, L-alanine (Table 2 ). Because both of these amino acids are normal components of pentapeptide synthesis and structure, their presence would be expected to result in the production of the usual dipeptide termini. Such termini should bind to and be acted upon by the D,D-carboxypeptidase without any notable decrease in vancomycin resistance.
In summary, the findings of this study indicate that certain amino acids specifically interfere with the levels of acquired vancomycin resistance expressed in E. faecalis and E. faecium. Although these results are consistent with major aspects of both the modified ligase-dehydrogenase mechanism (3, 4) and the D,D-carboxypeptidase mechanism (1, 9) of resistance, more studies are needed to establish the phenomena underlying the amino acid effect described in this report. Such information should be useful for planning further studies designed to elucidate the complex phenomena underlying enterococcal glycopeptide resistance.
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